| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Frédéric London, Alice De Haan, Zohra Benyahia, Gaëtane Landenne, Thierry Duprez, Vincent van Pesch, Souraya El Sankar. Uncovering heterogeneous cognitive trajectories in relapsing-remitting multiple sclerosis: a longitudinal study. Acta neurologica Belgica. 2025-03-15. PMID:40087234. |
cognitive impairment (ci) frequently occurs in relapsing-remitting multiple sclerosis (rrms) and is assumed to be irreversible. |
2025-03-15 |
2025-03-18 |
Not clear |
| Eman M Khedr, Mahmoud M Hassan, Mohamed Yosri Ezzeldeen, Mohamed Safwat El-Kady, Mohamed A El-Mokhtar, Abd Elaziz Shokr. Motor symptoms at onset and manual dexterity predict cognitive impairment in drug-naïve individuals with multiple sclerosis. Journal of neuroimmunology. vol 401. 2025-03-01. PMID:40022906. |
even in the early stages, cognitive impairment (ci) is commonly seen in multiple sclerosis (ms) patients. |
2025-03-01 |
2025-03-05 |
Not clear |
| Zheng Liao, Chenguang Su, Jian Li, Jinlong Li. Causal association of metformin treatment with diverse immune-mediated inflammatory diseases: A Mendelian randomization analysis. Medicine. vol 104. issue 6. 2025-02-10. PMID:39928815. |
the mr analysis indicated that metformin treatment could reduce the risk of rheumatoid arthritis (ra) (or = 0.018, 95% ci: 1.33 × 10-3-0.233, p = .002), multiple sclerosis (ms) (or = 0.966, 95% ci: 0.936-0.997, p = .030) and primary sclerosing cholangitis (psc) (or = 6.82 × 10-4, 95% ci: 7.83 × 10-6-5.93 × 10-2, p = .001). |
2025-02-10 |
2025-02-13 |
Not clear |
| Eleonora Virgilio, Valentina Ciampana, Chiara Puricelli, Paola Naldi, Angelo Bianchi, Umberto Dianzani, Domizia Vecchio, Cristoforo Com. Biomarkers of Intrathecal Synthesis May Be Associated with Cognitive Impairment at MS Diagnosis. International journal of molecular sciences. vol 26. issue 2. 2025-01-25. PMID:39859538. |
the pathophysiology of cognitive impairment (ci) in multiple sclerosis (ms) remains unclear. |
2025-01-25 |
2025-01-28 |
Not clear |
| Rojin Sarallah, Shima Jahani, Alireza Soltani Khaboushan, Amir Kian Moaveni, Maryam Amiri, Masoumeh Majidi Zolbi. The role of CXCL12/CXCR4/CXCR7 axis in cognitive impairment associated with neurodegenerative diseases. Brain, behavior, & immunity - health. vol 43. 2025-01-21. PMID:39834554. |
neurodegenerative diseases, including alzheimer's disease (ad), parkinson's disease (pd), multiple sclerosis (ms), and amyotrophic lateral sclerosis (als), are characterized by progressive neuronal loss and cognitive impairment (ci). |
2025-01-21 |
2025-01-23 |
Not clear |
| Senne B Lageman, Amy Jolly, Nitin Sahi, Ferran Prados, Baris Kanber, Arman Eshaghi, Carmen Tur, Cyrus Eierud, Vince D Calhoun, Menno M Schoonheim, Declan T Char. Explaining cognitive function in multiple sclerosis through networks of grey and white matter features: a joint independent component analysis. Journal of neurology. vol 272. issue 2. 2025-01-15. PMID:39812878. |
cognitive impairment (ci) in multiple sclerosis (ms) is only partially explained by whole-brain volume measures, but independent component analysis (ica) can extract regional patterns of damage in grey matter (gm) or white matter (wm) that have proven more closely associated with ci. pathology in gm and wm occurs in parallel, and so patterns can span both. |
2025-01-15 |
2025-01-17 |
Not clear |
| Ermelinda De Meo, Emilio Portaccio, Raffaello Bonacchi, Jasmine Giovannoli, Claudia Niccolai, Maria Pia Amat. An update on the treatment and management of cognitive dysfunction in patients with multiple sclerosis. Expert review of neurotherapeutics. 2025-01-13. PMID:39801437. |
cognitive impairment (ci) occurs in 34-70% of multiple sclerosis (ms) patients, significantly impacting quality of life. |
2025-01-13 |
2025-01-16 |
Not clear |
| Lorenzo Barba, Lorenzo Gaetani, Silvia Sperandei, Elena Di Sabatino, Samir Abu-Rumeileh, Steffen Halbgebauer, Patrick Oeckl, Petra Steinacker, Lucilla Parnetti, Massimiliano Di FIlippo, Markus Ott. CSF synaptic biomarkers and cognitive impairment in multiple sclerosis. Journal of neurology. vol 272. issue 1. 2024-12-21. PMID:39708160. |
people with multiple sclerosis (pwms) experience various degrees of cognitive impairment (ci). |
2024-12-21 |
2024-12-24 |
Not clear |
| Zachary Leibovit-Reiben, Hannah Godfrey, Patrick Jedlowski, Rebecca Thied. Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System. Melanoma research. 2024-12-10. PMID:39656586. |
several novel associations were identified; including epidural lipomatosis (ror: 320.07, 95% ci: 123.76-827.77 for v + c), peripheral nerve lesion (ror: 185.64, 95% ci: 73.95-466.03 for v + c), guillain-barre syndrome (rors: 8.80, 2.94, and 11.79, 95% cis: 3.65-21.22, 1.40-6.19, and 5.87-23.66 for v + c, d + t, and e + b), demyelinating polyneuropathy (rors: 24.72 and 78.98, 95% ci: 8.16-74.86 and 24.84-251.13 for d + t and e + b), and multiple sclerosis (ror: 5.90, 95% ci: 3.06-11.40 for d + t) in melanoma patients. |
2024-12-10 |
2024-12-21 |
Not clear |
| Alireza Kooshki, Reyhane Farmani, Alireza Amirabadizadeh, Omid Mehrpour, Mohammad Javad Sanjari, Samaneh Nakhae. Essential and toxic metal concentrations in biological samples of multiple sclerosis patients: A systematic review and meta-analysis. PloS one. vol 19. issue 12. 2024-12-06. PMID:39642137. |
results from the pooled data, analyzed using a random-effects model, revealed higher levels of as (hedge's g = 4.00 μg/l, 95% ci = 2.03 to 5.98, p <0.001; i2 = 97.69%, p<0.001) and cd (hedge's g = 1.20 μg/l, 95% ci = 0.13 to 2.27, p = 0.028; i2 = 97.99%, p<0.001) in multiple sclerosis patients compared to healthy ones. |
2024-12-06 |
2024-12-09 |
human |
| Abdorreza Naser Moghadasi, Omid Mirmosayyeb, Sara Bagherieh, Mohammad Ali Sahraian, Mahsa Ghajarzade. Computerized cognitive rehabilitation in patients with multiple sclerosis (MS): A systematic review and meta-analysis. Caspian journal of internal medicine. vol 16. issue 1. 2024-12-02. PMID:39619744. |
cognitive impairment (ci) is one of the main features of multiple sclerosis (ms). |
2024-12-02 |
2024-12-06 |
Not clear |
| Chunyi Lyu, Yan Wang, Ruirong X. Mendelian randomization analysis reveals causal effects of inflammatory bowel disease and autoimmune hyperthyroidism on diffuse large B-cell lymphoma risk. Scientific reports. vol 14. issue 1. 2024-11-26. PMID:39587169. |
the ivw results revealed no associations between the other seven ads and dlbcl: asthma (or = 0.782, 95% ci 0.395-1.546, p = 0.159), psoriasis (or = 0.842, 95% ci 0.669-1.060, p = 0.143), type 1 diabetes (or = 1.071, 95% ci 0.860-1.334, p = 0.537), multiple sclerosis (or = 1.331, 95% ci 0.941-1.883, p = 0.105), sarcoidosis (or = 1.324, 95% ci 0.861-2.038, p = 0.200), ankylosing spondylitis (or = 1.884, 95% ci 0.776-4.573, p = 0.161), and celiac disease (or = 1.003, 95% ci 0.854-1.178, p = 0.969). |
2024-11-26 |
2024-11-28 |
Not clear |
| Zachary L Weinstock, Ralph H B Benedic. Cognitive Relapse in Multiple Sclerosis: New Findings and Directions for Future Research. NeuroSci. vol 3. issue 3. 2024-11-01. PMID:39483431. |
multiple sclerosis (ms) is a chronic inflammatory, demyelinating disease of the central nervous system, often presenting with brain atrophy and cognitive impairment (ci). |
2024-11-01 |
2024-11-03 |
Not clear |
| Michela Bossa, Nicola Manocchio, Ornella Argent. Non-Pharmacological Treatments of Cognitive Impairment in Multiple Sclerosis: A Review. NeuroSci. vol 3. issue 3. 2024-11-01. PMID:39483435. |
cognitive impairment (ci) represents a common symptom in patients suffering from multiple sclerosis (ms), which can affect every stage of the disease course. |
2024-11-01 |
2024-11-03 |
Not clear |
| Emilio Portaccio, Maria Pia Amat. Cognitive Impairment in Multiple Sclerosis: An Update on Assessment and Management. NeuroSci. vol 3. issue 4. 2024-11-01. PMID:39483763. |
cognitive impairment (ci) is a core feature of multiple sclerosis (ms) and affects up to 65% of patients in every phase of the disease, having a deep impact on all aspects of patients' lives. |
2024-11-01 |
2024-11-03 |
Not clear |
| Nasim Rezaeimanesh, Naghme Abbasi Kasbi, Roghayyeh Saeedi, Mohammad Ali Sahraian, Soodeh Razeghi Jahromi, Abdorreza Naser Moghadas. Investigating the Correlation Between Cognitive Function and Fasting Blood Sugar, Fasting Insulin Level and Insulin Sensitivity in Patients With Multiple Sclerosis. Endocrinology, diabetes & metabolism. vol 7. issue 6. 2024-10-07. PMID:39374429. |
there has been a surge in interest in identifying the factors that impact cognitive impairment (ci) in patients with multiple sclerosis (ms). |
2024-10-07 |
2024-10-10 |
Not clear |
| Gabriel de Deus Vieira, Fernanda Ferrão Antônio, Alfredo Damascen. Association between paramagnetic rim lesions with cognitive impairment in pediatric multiple sclerosis. Multiple sclerosis and related disorders. vol 91. 2024-09-14. PMID:39276597. |
pediatric onset multiple sclerosis (poms) patients are at risk for cognitive impairment (ci). |
2024-09-14 |
2024-09-18 |
Not clear |
| Jessica Podda, Federica Di Antonio, Andrea Tacchino, Ludovico Pedullà, Erica Grange, Mario Alberto Battaglia, Giampaolo Brichetto, Michela Ponzi. A taxonomy of cognitive phenotypes in Multiple Sclerosis: a 1-year longitudinal study. Scientific reports. vol 14. issue 1. 2024-09-02. PMID:39223279. |
since ci is highly variable in severity and progression, monitoring cognitive phenotypes over time may be useful to identify trajectory of cognitive decline in multiple sclerosis (ms). |
2024-09-02 |
2024-09-05 |
Not clear |
| Xiaohua Wang, Shangqing Liu, Zichun Yan, Feiyue Yin, Jinzhou Feng, Hao Liu, Yanbing Liu, Yongmei L. Radiomics Nomograms Based on Multi-sequence MRI for Identifying Cognitive Impairment and Predicting Cognitive Progression in Relapsing-Remitting Multiple Sclerosis. Academic radiology. 2024-08-28. PMID:39198138. |
to build radiomics nomograms based on multi-sequence mri to facilitate the identification of cognitive impairment (ci) and prediction of cognitive progression (cp) in patients with relapsing-remitting multiple sclerosis (rrms). |
2024-08-28 |
2024-09-01 |
Not clear |
| Stefano Ziccardi, Agnese Tamanti, Claudia Ruggieri, Maddalena Guandalini, Damiano Marastoni, Valentina Camera, Luigi Montibeller, Valentina Mazziotti, Stefania Rossi, Milena Calderone, Francesca Benedetta Pizzini, Stefania Montemezzi, Roberta Magliozzi, Massimiliano Calabres. CSF Parvalbumin Levels at Multiple Sclerosis Diagnosis Predict Future Worse Cognition, Physical Disability, Fatigue, and Gray Matter Damage. Neurology(R) neuroimmunology & neuroinflammation. vol 11. issue 6. 2024-08-23. PMID:39178066. |
cognitive impairment (ci) in multiple sclerosis (ms) is frequent and determined by a complex interplay between inflammatory and neurodegenerative processes. |
2024-08-23 |
2024-08-26 |
Not clear |